Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Issues 43 Product-Specific Guidances

Comprises 33 New Guidances And 10 Revised Documents

Executive Summary

The latest update from the FDA has brought 43 new and updated product-specific guidances for generic drug development, including dedicated documents on complex generics such as aerosols, powders and sprays.

You may also be interested in...



The Factory Floor: Carbogen Amcis, PCI Pharma And Vetter Expand In Europe

Carbogen Amcis, LGM Pharma, Vetter and PCI Pharma are focusing on expanding their businesses, while ChemWerth has filed its 500th drug master file for clevidipine with the FDA.

FDA Publishes 69 Product-Specific Guidances

The FDA has issued 69 product-specific guidances for generic drug development, comprising 26 new guidances and 43 revised documents.

GDUFA Research Supports Complex Generics

Given the challenges faced by complex generics, GDUFA-funded research is attempting to provide data to help assess and approve ANDAs for complex generic products.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel